

## Enrollment and Prescription Form

- Once completed, please fax this form to Oriahnn<sup>™</sup> Complete at 1-855-662-5355.
- Give your patient the Welcome Sheet.

**Questions?** Call 1-800-ORIAHNN (1-800-674-2466).

All fields marked with an asterisk (\*) are required. The HCP and the patient or legally authorized person should fill out this form completely before leaving the office.

### 1 Patient Information\*

To be completed by patient or legally authorized person:

Patient First Name: \_\_\_\_\_ Last Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Preferred Shipping Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_

Phone # (mobile preferred): \_\_\_\_\_ Patient Email: \_\_\_\_\_

Best time to call (Monday-Friday):  Anytime  Morning  Afternoon  Evening Oriahnn Complete will confirm shipping details when they call.

Check here if an interpreter is needed.

**By enrolling, you may have access to your own Nurse Ambassador. Ambassadors do not give medical advice and are trained to direct patients to their healthcare professionals for treatment-related advice, including further referrals. To learn about AbbVie's privacy practices and your privacy choices, visit [www.abbvie.com/privacy.html](http://www.abbvie.com/privacy.html)**

I would like to receive news and updates about AbbVie's products, clinical trials, research opportunities, programs, and other information that may be of interest to me.

### 2 Insurance Information\*

Check box if your doctor's office will copy and attach insurance cards.

Beneficiary/Cardholder Name: \_\_\_\_\_ Medical Insurance: \_\_\_\_\_

Medical Insurance ID #: \_\_\_\_\_ Group #: \_\_\_\_\_

Prescription Insurance: \_\_\_\_\_

RX Group #: \_\_\_\_\_ RX ID #: \_\_\_\_\_

RX Bin #: \_\_\_\_\_ RX PCN #: \_\_\_\_\_

### ▼ For Healthcare Provider (HCP) Use Only ▼

### 3 Diagnosis\*

Heavy bleeding associated with uterine fibroids.

### 4 Prescriber Information

HCP First Name\*: \_\_\_\_\_ Last Name\*: \_\_\_\_\_ NPI #\*: \_\_\_\_\_

HCP Address\*: \_\_\_\_\_ City\*: \_\_\_\_\_ State\*: \_\_\_\_\_ ZIP\*: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_ Office Phone #\*: \_\_\_\_\_

Office Contact Email: \_\_\_\_\_ Office Fax #: \_\_\_\_\_

Preferred method of contact:  Phone  Fax

### 5 Oriahnn Complete Prescriptions

#### 28-day Free Trial (For ALL Patients)<sup>†</sup>

Sign below to ensure your patient receives a free 28-day trial to determine if ORIAHNN is the right treatment for her

ORIAHNN 300 mg capsules, 1 capsule PO QAM and 1 capsule PO QPM, quantity: 1 month (#56) capsules

Prescriber's Signature: \_\_\_\_\_

Date: \_\_\_\_ / \_\_\_\_ / \_\_\_\_ NO REFILLS

Preferred Retail Pharmacy: \_\_\_\_\_

Please review prescriber certification statement on page 3 before signing

#### To Continue on Treatment<sup>‡</sup>

Sign below in the event there is a **delay or denial in your patient's commercial insurance**. By signing, you agree to continue to pursue insurance coverage for ORIAHNN for as long as the patient remains on therapy, as described in the program terms and conditions contained on page 3

ORIAHNN 300 mg capsules, 1 capsule PO QAM and 1 capsule PO QPM, quantity: 1 month (#56) capsules

Prescriber's Signature: \_\_\_\_\_

Date: \_\_\_\_ / \_\_\_\_ / \_\_\_\_ Refills: \_\_\_\_\_ Restrictions per state may apply

Pharmacy Phone #: \_\_\_\_\_

SIGN HERE<sup>§</sup>

## INDICATION

ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. Use of ORIAHNN should be limited to 24 months due to the risk of continued bone loss, which may not be reversible.

## IMPORTANT SAFETY INFORMATION

### THROMBOEMBOLIC AND VASCULAR EVENTS

Estrogen and progestin combinations, including ORIAHNN, increase the risk of thrombotic or thromboembolic disorders, including pulmonary embolism, deep vein thrombosis, stroke, and myocardial infarction, especially in women at increased risk for these events.

ORIAHNN is contraindicated in women with current or a history of thrombotic or thromboembolic disorders and in women at increased risk for these events, including women over 35 years of age who smoke and women with uncontrolled hypertension.

### CONTRAINDICATIONS

- ORIAHNN is contraindicated in women at a high risk of arterial, venous thrombotic, or thromboembolic disorders; who are pregnant; with known osteoporosis; current or history of breast cancer or other hormonally sensitive malignancies; known hepatic impairment or disease; undiagnosed abnormal uterine bleeding; known anaphylactic reaction, angioedema, or hypersensitivity to ingredients of ORIAHNN; or with concomitant use of organic anion transporting polypeptide (OATP) 1B1 inhibitors that are known or expected to significantly increase elagolix plasma concentrations.

### WARNINGS AND PRECAUTIONS

#### Thromboembolic Disorders and Vascular Events

- ORIAHNN is contraindicated in women with current or a history of thrombotic or thromboembolic disorders and in women at increased risk for these events. Components of ORIAHNN increase the risk of thrombotic or thromboembolic disorders, including pulmonary embolism, deep vein thrombosis, stroke, and myocardial infarction, especially in women at high risk for these events. In general, the risk is greatest among women over 35 years of age who smoke, and women with uncontrolled hypertension, dyslipidemia, vascular disease, or obesity.
- Discontinue ORIAHNN if an arterial or venous thrombotic, cardiovascular, or cerebrovascular event occurs. If feasible, discontinue ORIAHNN at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization. Stop ORIAHNN if there is sudden, unexplained partial or complete loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions and evaluate for retinal vein thrombosis immediately.

#### Bone Loss

- ORIAHNN is contraindicated in women with known osteoporosis. ORIAHNN may cause a decrease in bone mineral density (BMD) in some patients, which is greater with increasing duration of use and may not be completely reversible after stopping treatment.
- The impact of ORIAHNN-associated decreases in BMD on long-term bone health and future fracture risk is unknown. Consider the benefits and risks of ORIAHNN in patients with a history of low-trauma fracture or other risk factors for osteoporosis or bone loss, including those taking medications that may decrease BMD (e.g., systemic or chronic inhaled corticosteroids, anticonvulsants, or proton pump inhibitors).
- Assessment of BMD by dual-energy X-ray absorptiometry (DXA) is recommended at baseline and periodically thereafter. Consider discontinuing ORIAHNN if the risk associated with bone loss exceeds the potential benefit of treatment. Limit the duration of use to 24 months to reduce the extent of bone loss.

#### Hormonally Sensitive Malignancies

- ORIAHNN is contraindicated in women with current or a history of breast cancer and in women at increased risk for hormonally sensitive malignancies, such as those with mutations in BRCA genes.
- The use of estrogen alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. Surveillance measures, such as breast examinations and regular mammography, are recommended. Discontinue ORIAHNN if a hormonally sensitive malignancy is diagnosed.

#### Suicidal Ideation, Suicidal Behavior, and Exacerbation of Mood Disorders

- Depression, depressed mood, and/or tearfulness were reported at a higher incidence in women taking ORIAHNN (3%) compared with placebo (1%) in the Phase 3 clinical trials. Suicidal ideation and behavior, including a completed suicide, occurred in women treated with lower doses of elagolix in clinical trials conducted for a different indication.
- Promptly evaluate patients with depressive symptoms to determine whether the risks of continued therapy outweigh the benefits. Patients with new or worsening depression, anxiety, or other mood changes should be referred to mental health professional, as appropriate.
- Advise patients to seek immediate medical attention for suicidal ideation and behavior. Reevaluate the benefits and risks of continuing ORIAHNN if such events occur.

#### Hepatic Impairment and Transaminase Elevations

- ORIAHNN is contraindicated in women with known hepatic impairment or disease.
- Transaminase elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) occurred with ORIAHNN in Phase 3 clinical trials. No pattern in time to onset of these liver transaminase elevations was identified. Transaminase levels returned to baseline within 4 months after peak values in these patients.
- Instruct patients to promptly seek medical attention in case of symptoms or signs that may reflect liver injury, such as jaundice.

#### Elevated Blood Pressure

- ORIAHNN is contraindicated in women with uncontrolled hypertension. Maximum mean increases in systolic blood pressure occurred at Month 5, and a mean maximum increase in diastolic blood pressure occurred at Month 4 in ORIAHNN-treated women, as compared to placebo-treated women.
- For women with well-controlled hypertension, continue to monitor blood pressure and stop ORIAHNN if blood pressure rises significantly. Monitor blood pressure in normotensive women treated with ORIAHNN.

#### Gallbladder Disease or History of Cholestatic Jaundice

- Studies among estrogen users suggest a small increased relative risk of developing gallbladder disease. For women with a history of cholestatic jaundice associated with past estrogen use or with pregnancy, assess the risk-benefit of continuing therapy. Discontinue ORIAHNN if jaundice occurs.

#### Change in Menstrual Bleeding Pattern and Reduced Ability to Recognize Pregnancy

- ORIAHNN may delay the ability to recognize the occurrence of a pregnancy because it may reduce the intensity, duration, and amount of menstrual bleeding. Perform pregnancy testing if pregnancy is suspected and discontinue ORIAHNN if pregnancy is confirmed.
- The effect of hormonal contraceptives on the efficacy of ORIAHNN is unknown. Advise women to use non-hormonal contraception during treatment and for 1 week after discontinuing ORIAHNN.

#### Effects on Carbohydrate and Lipid Metabolism

- ORIAHNN may decrease glucose tolerance and result in increased glucose levels. More frequent monitoring in ORIAHNN-treated women with prediabetes and diabetes may be needed.
- In women with preexisting hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. Use of elagolix is associated with increases in total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and serum triglycerides. Monitor lipid levels and consider discontinuing ORIAHNN if hypercholesterolemia or hypertriglyceridemia worsens.

#### Alopecia

- In Phase 3 clinical trials, more women experienced alopecia, hair loss, and hair thinning with ORIAHNN (3.5%) compared to placebo (1.0%). In almost one-third of affected ORIAHNN-treated women, alopecia was the reason for discontinuing treatment. No specific pattern was described. In the majority of these women, hair loss was continuing when ORIAHNN was stopped. Whether the hair loss is reversible is unknown. Consider discontinuing ORIAHNN if hair loss becomes a concern.

#### Effect on Other Laboratory Results

- The use of estrogen and progestin combinations may raise serum concentrations of binding proteins (e.g., thyroid-binding globulin, corticosteroid-binding globulin), which may reduce the free thyroid or corticosteroid hormone levels. Patients with hypothyroidism and hypoadrenalism may require higher doses of thyroid hormone or cortisol replacement therapy, respectively.
- The use of estrogen and progestin may also affect the levels of sex hormone-binding globulin, coagulation factors, lipids, and glucose.

#### RISK OF ALLERGIC REACTIONS DUE TO THE INACTIVE INGREDIENT (FD&C YELLOW NO. 5)

- ORIAHNN contains FD&C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

#### ADVERSE REACTIONS

- Most common adverse reactions occurring in ≥5% of women receiving ORIAHNN in clinical trials were hot flush, headache, fatigue, and metrorrhagia.

These are not all of the possible side effects of ORIAHNN.

Safety and effectiveness of ORIAHNN in pediatric patients have not been established.



Oriahnn™

elagolix, estradiol and norethindrone acetate capsules  
and elagolix capsules 300 mg/1 mg/0.5 mg and 300 mg

## Oriahnn Complete Terms and Conditions

<sup>1</sup>The ORIAHNN free trial provides a single 28-day trial supply of ORIAHNN at no cost to new patients residing in the United States with a valid prescription for an FDA-approved indication of ORIAHNN and who enroll in Oriahnn Complete. The trial is intended solely to allow new patients not currently taking ORIAHNN to determine with their healthcare provider whether ORIAHNN is right for them. There is no obligation to continue use of ORIAHNN after the trial has concluded and this program does not guarantee insurance coverage. Eligible patients are limited to one 28-day trial supply and may not re-enroll. The ORIAHNN trial supply will be dispensed only through an AbbVie-authorized pharmacy to the patient's home address and may not be sold or further distributed. No claims for payment may be submitted to any third party insurance plan for product dispensed by program. AbbVie reserves the right to change or discontinue the trial at any time without notice. The trial is not health insurance and is not a discount, coupon, rebate or financial assistance program. Limitations may apply.

<sup>4</sup>Program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient's health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be eligible to participate in program. Available to patients between the ages of 18-63 with commercial prescription insurance coverage who meet eligibility criteria. Eligibility: Patients must be diagnosed with heavy menstrual bleeding related to uterine fibroids, have a valid prescription for ORIAHNN, and participate in a commercial insurance plan that has denied or not yet made a formulary decision for ORIAHNN. Once the patient's insurance plan has made a formulary decision and established a process for reviewing coverage requests for ORIAHNN, continued eligibility for the program requires the submission of a Prior Authorization prior to the next scheduled dose and appeal of the coverage denial within 180 days. Program provides ORIAHNN at no charge to patients for up to 2 years or until they receive insurance coverage approval, whichever occurs earlier. Offer subject to change or discontinuance without notice. This is not health insurance, and program does not guarantee insurance coverage.

To be eligible for ORIAHNN coverage beyond the first month, patients must have (1) commercial insurance, (2) a valid Rx for ORIAHNN, and (3) experienced a delay or denial in insurance determination. Prescription to be filled through an AbbVie-authorized pharmacy. I understand that faxing this form to Oriahnn Complete will result in an original copy being simultaneously transmitted to the AbbVie-authorized pharmacy under this section.

## Prescriber Certification

<sup>5</sup>I certify that ORIAHNN is medically necessary and that the diagnosis and other information provided is accurate to the best of my knowledge. I certify that I am the prescriber who has prescribed ORIAHNN to the previously identified patient, and that I provided the patient with a description of the Oriahnn Complete patient support program. I authorize Oriahnn Complete to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy. I understand that the no-charge resource through Oriahnn Complete may support patients during the first month on treatment. I certify that I will not seek reimbursement from any third-party payer for any no-charge product dispensed by an AbbVie-authorized pharmacy.

Please see Full Indication and Important Safety Information, including  
BOXED WARNING on THROMBOEMBOLIC AND VASCULAR EVENTS, on page 2.  
Please see Full Prescribing Information at [www.rxabbvie.com/pdf/oriahnn\\_pi.pdf](http://www.rxabbvie.com/pdf/oriahnn_pi.pdf)

abbvie ©2021 AbbVie Inc. North Chicago, IL 60064 US-ORIA-210048 February 2021

 **Oriahnn™**  
elagolix, estradiol and norethindrone acetate capsules  
and elagolix capsules 300 mg/1 mg/0.5 mg and 300 mg

# Welcome to Oriahnn™ Complete!

Starting a new medication can raise a lot of questions—that's why we're here to help whenever you may need us.

## Wondering what's next?

You may receive a call from Oriahnn Complete if additional information is needed. To get your medication as soon as possible, please pick up our call. We'll help you:

1. Understand your insurance coverage for ORIAHNN.
2. Navigate the steps needed to get your medication.
3. Find possible ways to save on future ORIAHNN refills. (You could pay as little as \$5\* a month.)
4. Get answers to your questions about ORIAHNN with personalized, one-on-one support by requesting an Oriahnn Complete Nurse Ambassador.†

Oriahnn<sup>™</sup>COMPLETE

You could save on your prescription.  
Request an Oriahnn Complete Savings card.  
Call 1-800-ORIAHNN.

Please see Important Safety Information and accompanying Full Prescribing Information, including Medication Guide, and discuss with your doctor.



Oriahnn<sup>™</sup>

elagolix, estradiol and norethindrone acetate capsules and elagolix capsules 300 mg/1 mg/0.5 mg and 300 mg

**Have questions? Want to connect with a Nurse Ambassador†?**  
**Call 1-800-674-2466, Monday through Friday, 8 AM–8 PM ET.**

### SAFETY CONSIDERATIONS

ORIAHNN may increase your chances of heart attack, stroke, or blood clots, especially if you are over 35 years of age and smoke, have uncontrolled high blood pressure, high cholesterol, diabetes, and/or are obese. Stop taking ORIAHNN and talk to a doctor right away if you have symptoms of a heart attack, stroke, or blood clot.

\*See Terms and Conditions on the last page.

†Nurse Ambassadors are provided by AbbVie and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

Oriahnn<sup>™</sup>COMPLETE

Please see Important Safety Information on pages 6 and 7.

Please see Full Prescribing Information, including Medication Guide, at [www.rxabbvie.com/pdf/oriahnn\\_pi.pdf](http://www.rxabbvie.com/pdf/oriahnn_pi.pdf) and discuss with your doctor.



Oriahnn<sup>™</sup>

elagolix, estradiol and norethindrone acetate capsules and elagolix capsules 300 mg/1 mg/0.5 mg and 300 mg



Oriahnn<sup>™</sup>COMPLETE

## Get one-on-one support

Your Nurse Ambassador<sup>†</sup> can help you stay on track with your prescribed treatment plan and give you personalized support—right from the start. They can help you better understand both your condition and ORIAHNN.



Connect with a Nurse Ambassador by calling 1-800-ORIAHNN (1-800-674-2466), Monday through Friday, 8 AM–8 PM ET

For more information, visit [Oriahnn.com](https://www.abbvie.com)

The categories of personal information collected in the Enrollment and Prescription Form include contact, insurance, prescription, and medical history information. The personal information collected will be used to provide and manage the Oriahnn Complete program and to perform research and analytics on a de-identified basis. For more information about the categories of personal information collected by AbbVie and the purposes for which AbbVie uses personal information, visit [www.abbvie.com/privacy.html](https://www.abbvie.com/privacy.html)

Please see Important Safety Information on pages 6 and 7.

Please see Full Prescribing Information, including Medication Guide, at [www.rxabbvie.com/pdf/oriahnn\\_pi.pdf](https://www.rxabbvie.com/pdf/oriahnn_pi.pdf) and discuss with your doctor.



Oriahnn<sup>™</sup>

elagolix, estradiol and norethindrone acetate capsules  
and elagolix capsules 300 mg/1 mg/0.5 mg and 300 mg

## USE

ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) is a prescription medicine used to control heavy menstrual bleeding related to uterine fibroids in women before menopause. It should not be taken for more than 24 months. It is not known if ORIAHNN is safe and effective in children under 18 years of age.

## IMPORTANT SAFETY INFORMATION

### What is the most important information I should know about ORIAHNN?

ORIAHNN may cause serious side effects, including:

#### • Cardiovascular Conditions

– ORIAHNN may increase your chances of heart attack, stroke, or blood clots, especially if you are over 35 years of age and smoke, have uncontrolled high blood pressure, high cholesterol, diabetes, or are obese. **Stop taking ORIAHNN and call your healthcare provider right away or go to the nearest hospital emergency room right away if you have:**

- Leg pain or swelling that will not go away
- Sudden shortness of breath
- Double vision, bulging of the eyes, or sudden blindness (partial or complete)
- Pain or pressure in your chest, arm, or jaw
- Sudden, severe headache unlike your usual headaches
- Weakness or numbness in an arm or leg, or trouble speaking

#### • Bone Loss (Decreased Bone Mineral Density [BMD])

- While taking ORIAHNN, your estrogen levels may be low. Low estrogen levels can lead to BMD loss.
- If you have bone loss on ORIAHNN, your BMD may improve after you stop taking ORIAHNN, but complete recovery may not occur. It is unknown if these BMD changes could increase your risk for broken bones as you age. For this reason, **you should not take ORIAHNN for more than 24 months.**
- Your healthcare provider may order an X-ray test called a DXA scan to check your bone mineral density when you start taking ORIAHNN and periodically after you start.
- Your doctor may advise you to take vitamin D and calcium supplements as part of a healthy lifestyle.

#### • Effects on Pregnancy

- **Do not take ORIAHNN** if you are pregnant or trying to become pregnant, as it may increase the risk of early pregnancy loss.
- **If you think you may be pregnant**, stop taking ORIAHNN right away and call your HCP.
- ORIAHNN can decrease your menstrual bleeding or result in no menstrual bleeding at all, making

it hard to know if you are pregnant. Watch for other pregnancy signs like breast tenderness, weight gain, and nausea.

- ORIAHNN does not prevent pregnancy. You will need to use effective methods of birth control while taking ORIAHNN and for 1 week after you stop taking ORIAHNN. Examples of effective methods can include condoms or spermicide, which do not contain hormones.
- Talk to your HCP about which birth control to use during treatment with ORIAHNN. Your HCP may change the birth control you are on before you start taking ORIAHNN.

#### Do not take ORIAHNN if you:

- Have or have had:
  - A stroke or heart attack
  - A problem that makes your blood clot more than normal
  - Blood circulation disorder
  - Certain heart valve problems or heart rhythm abnormalities that can cause blood clots to form in the heart
  - Blood clots in your legs (deep vein thrombosis), lungs (pulmonary embolism), or eyes (retinal thrombosis)
  - High blood pressure not well controlled by medicine
  - Diabetes with kidney, eye, nerve, or blood vessel damage
  - Certain kinds of headaches with numbness, weakness, or changes in vision, or have migraine headaches with aura if you are over age 35
  - Breast cancer or any cancer that is sensitive to female hormones
  - Osteoporosis
  - Unexplained vaginal bleeding that has not been diagnosed
  - Liver problems including liver disease
- Smoke and are over 35 years old
- Are taking medicines known as strong OATP1B1 inhibitors that are known or expected to significantly increase the blood levels of elagolix. Ask your HCP if you are not sure if you are taking this type of medicine.
- Have had a serious allergic reaction to elagolix, estradiol, norethindrone acetate, or any of the ingredients in ORIAHNN. Ask your HCP if you are not sure.
- FD&C Yellow No. 5 (tartrazine) is an ingredient in ORIAHNN, which may cause an allergic type reaction such as bronchial asthma in some patients who are also allergic to aspirin.

#### What should I discuss with my HCP before taking ORIAHNN?

Tell your HCP about all your medical conditions, including if you:

Please see additional Important Safety Information on page 7.

Please see Full Prescribing Information, including Medication Guide, at [www.rxabbvie.com/pdf/oriahnn\\_pi.pdf](http://www.rxabbvie.com/pdf/oriahnn_pi.pdf) and discuss with your doctor.

- Have or have had:
  - Broken bones or other conditions that may cause bone problems
  - Depression, mood swings, or suicidal thoughts or behavior
  - Yellowing of the skin or eyes (jaundice) or jaundice caused by pregnancy (cholestasis of pregnancy)
- Are scheduled for surgery. ORIAHNN may increase your risk of blood clots after surgery. Your doctor may advise you to stop taking ORIAHNN before you have surgery. If this happens, talk to your HCP about when to restart ORIAHNN after surgery.
- Are pregnant or think you may be pregnant.
- Are breastfeeding. It is not known if ORIAHNN can pass into your breastmilk. Talk to your HCP about the best way to feed your baby if you take ORIAHNN.

**Tell your HCP about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Women on thyroid or cortisol replacement therapy may need increased doses of the hormone.

Keep a list of your medicines with you to show to your HCP and pharmacist when you get a new medicine.

### What should I avoid while taking ORIAHNN?

- Avoid grapefruit and grapefruit juice during treatment with ORIAHNN since they may affect the level of ORIAHNN in your blood, which may increase side effects.

### What are the possible side effects of ORIAHNN?

**ORIAHNN can cause additional serious side effects, including:**

- **Suicidal thoughts, suicidal behavior, and worsening of mood.** ORIAHNN may cause suicidal thoughts or actions. **Call your HCP or get emergency medical help right away if you have any of these symptoms, especially if they are new, worse, or bother you:** thoughts about suicide or dying, attempts to commit suicide, new or worse depression or anxiety, or other unusual changes in behavior or mood. Pay attention to any changes, especially sudden changes, in your mood, behaviors, thoughts, or feelings.
- **Abnormal liver tests. Call your HCP right away if you have any of these signs and symptoms of liver problems:** jaundice, dark amber-colored urine, feeling tired, nausea and vomiting, generalized swelling, right upper stomach area pain, or bruising easily.
- **High blood pressure.** You should see your HCP to check your blood pressure regularly.

Please see additional Important Safety Information on page 6.

Please see Full Prescribing Information, including Medication Guide, at [www.rxabbvie.com/pdf/oriahnn\\_pi.pdf](http://www.rxabbvie.com/pdf/oriahnn_pi.pdf) and discuss with your doctor.

abbvie

©2021 AbbVie Inc. North Chicago, IL 60064  
US-ORIA-210048 February 2021

- **Gallbladder problems (cholestasis),** especially if you had cholestasis of pregnancy.
- **Increases in blood sugar, cholesterol, and fat (triglyceride) levels.**
- **Hair loss (alopecia).** Hair loss and hair thinning can happen while taking ORIAHNN, and it can continue even after you stop taking ORIAHNN. It is not known if this hair loss or hair thinning is reversible. Talk to your HCP if this is a concern for you.
- **Changes in laboratory tests,** including thyroid and other hormone, cholesterol, and blood clotting tests.

**The most common side effects of ORIAHNN include:** hot flashes, headache, fatigue, and irregular periods.

These are not all of the possible side effects of ORIAHNN. Tell your HCP if you have any side effect that bothers you or that does not go away. Call your HCP for medical advice about side effects.


Take ORIAHNN exactly as your HCP tells you. The recommended oral dosage of ORIAHNN is one yellow/white capsule in the morning and one blue/white capsule in the evening, with or without food.

This is the most important information to know about ORIAHNN. For more information, talk to your doctor or HCP.

**You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.**

**If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit [www.AbbVie.com/myAbbVieAssist](http://www.AbbVie.com/myAbbVieAssist) to learn more.**

Terms and Conditions apply. This benefit covers ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules). Eligibility: Available to patients with commercial prescription insurance coverage for ORIAHNN who meet eligibility criteria. Copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient's health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the Oriahnn Complete Savings Card and patient must call Oriahnn Complete at 1-800-ORIAHNN and stop use of the copay card. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from ORIAHNN, including the copay card, from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance.

 **Oriahnn™**  
elagolix, estradiol and norethindrone acetate capsules  
and elagolix capsules 300 mg/1 mg/0.5 mg and 300 mg